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Background 
Poor oral hygiene and colonization of dental plaque is likely 
to play an important role in the development of ventilator-
associated pneumonia (VAP) in many critically ill patients. 
Preliminary observations have suggested that dental plaque 
antiseptic decontamination (PAD) may reduce the frequency 
of VAP and ICU acquired bacteremia. 
Methods 
Design and setting: Prospective, multi-center, double-
blind, placebo-controlled trial in six French ICUs.  
Objective: To document the effect of gingival and dental 
plaque antiseptic decontamination on the rate of nosocomial 
bacteremias and respiratory infections acquired in the ICU. 
Patients and intervention: 228 non-edentulous patients 
requiring endotracheal intubation and mechanical ventilation 
with an anticipated ICU length of stay > 5 days were 
randomized to receive 0.2% chlorhexidine gel or placebo 
applied to dental and gingival surfaces three times daily for 
the duration of their ICU stay until day 28. 
Outcomes: The primary end point was the composite 
incidence of bacteremia, bronchitis and VAP acquired in the 
ICU. Secondary endpoints included ICU mortality, length of 
stay and medical and nursing care loads. Changes in 
bacterial colonization were evaluated in a subset of 
randomized patients. 
Results 
All baseline characteristics were similar between the treated 
and the placebo groups. The trial was stopped based on an 
interim analysis showing statistical futility. The incidence of 
nosocomial infections was 17.5% (13.2 per 1000 ICU days) 
in the placebo group and 18.4% (13.3 per 1000 ICU days) 
in the plaque antiseptic decontamination group (p=NS). No 
difference was observed in the incidence of ventilator-
associated pneumonia per ventilator or intubation days, 
mortality, length of stay, and care loads. On day 10, the 
number of positive dental plaque cultures was significantly 
lower in the treated group (29% vs. 66%; p<0.05). Highly 
resistant Pseudomonas, Acinetobacter, and Enterobacter 
species identified in late-onset ventilator-associated 
pneumonia and previously cultured from dental plaque were 
not eradicated by the antiseptic decontamination. No side 
effect was reported.  
Conclusion 
Gingival and dental plaque antiseptic decontamination 
significantly decreased the oropharyngeal colonization by 
aerobic pathogens in ventilated patients. However, its 
efficacy was insufficient to reduce the incidence of 
respiratory infections due to multiresistant bacteria. 
Commentary 
VAP remains a major cause of morbidity, mortality, and 
increased costs in the ICU [2]. Recent clinical practice 
guidelines recommend a variety of preventative measures, 
including orotracheal (rather than endotracheal) intubation, 
closed suctioning systems, weekly changes of heat and 
moisture exchangers, semi-recumbent positioning, and 
subglottic secretion drainage [3]. Although evidence from 
more than 50 clinical trials and ten meta-analyses 
demonstrate that selective decontamination of the digestive 
tract  (SDD) using topical antibiotics (+/- systemic 
antibiotics) is associated with decreased incidence of VAP, 
routine implementation of SDD has not been adopted by 
most intensivists because of concerns about the emergence 
of antibiotic-resistant pathogens. Topical application of an 
antiseptic, such as chlorhexidine, could be an attractive 
alternative for oropharyngeal decontamination. For 
example, chlorhexidine oral decontamination reduced the 
incidence of VAP in a low-risk population of cardiac surgical 
patients [4] and, recently, in mechanically ventilated 
medical-surgical ICU patients [5]. 
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Colonization of the oropharynx by pathogenic bacteria is a 
key step in the development of VAP. Poor oral hygiene and 
excess dental plaque are particularly troublesome sources 
of nosocomial infection. Notably, a single mm
3 of dental 
plaque contains ≥10
8 bacteria! Preliminary observations 
indicate that dental plaque antiseptic decontamination 
(PAD), in which an antiseptic is applied directly to dental 
and gingival surfaces, may reduce the frequency of VAP 
and ICU-acquired bacteremia [6].   
In this randomized controlled trial by Fourrier and 
colleagues [1], PAD with 0.2% chlorhexidine gel had no 
apparent impact on the incidence of VAP, bronchitis, or 
bacteremia. While eradication of bacteria from these areas 
might be expected to reduce oropharyngeal colonization 
and subsequent pneumonia, a number of methodological 
limitations may have reduced the likelihood of showing an 
impact for the intervention. Because rates of VAP were 
much lower than anticipated, the study was underpowered. 
Two-thirds of the subjects were considered infected at the 
time of ICU admission (primarily bronchitis and community-
acquired pneumonia) and prior antibiotic usage was not an 
exclusionary criterion for entry into the study, making 
interpretation of rates of new respiratory infections 
challenging at best. Failure to employ adjunctive mechanical 
debridement of dental plaque (i.e., tooth brushing) and to 
standardize recommended VAP prevention measures may 
have further obscured any potentially beneficial effect of 
PAD.  
Despite the negative results of this study, some interesting 
and potentially important observations emerged. These 
observations serve to emphasize the potential role of poor 
dental hygiene in the pathogenesis of VAP. Poor dental 
hygiene was apparent in 90% of the patients at the time of 
enrollment into the study. Of the 50% of dental plaque 
cultures that were positive for bacterial growth at the time of 
entry, approximately one third grew pathogenic aerobic 
Gram-negative rods. There was good concordance of dental 
plaque isolates with lung cultures in those who developed 
respiratory infection. These findings add to the growing 
body of evidence implicating poor oral hygiene as an 
important risk factor in the development of VAP in critically 
ill patients [7,8] and should serve to refocus our attention on 
the teeth and oropharynx as a reservoir for bacterial 
pathogens in transit to the lungs. Though the authors were 
not able to show a meaningful clinical benefit in this study, 
reducing bacterial colonization through PAD may still have 
the potential to favorably impact VAP, perhaps when 
coupled with other VAP preventative measures. 
Further clinical investigations are needed to address a 
number of outstanding questions and issues related to oral 
hygiene and VAP prevention. The development of simple 
and reproducible methods and tools to assess and define 
the state of dentition, oral hygiene, and bacterial burden 
would be of great value not only for research purposes but 
also for the integration of oropharyngeal care into routine 
clinical practice. Endotracheal tube fixation devices should 
be designed not only to enhance tube security but also to 
allow for easy access to the oropharynx without the need for 
removing them each time oral hygiene care is administered. 
Additional prospective studies are needed to identify oral 
hygiene strategies that are the most effective in taking a bite 
out of VAP!  
 
Recommendation 
Though the authors failed to show a benefit for 
chlorhexidine-based PAD, other randomized controlled 
studies have established that oral decontamination with 
topical antiseptics reduces the incidence of VAP [4,5,9]. 
Interventions to establish and maintain good oral hygiene in 
intubated patients should be part of a multifaceted approach 
to the prevention VAP.  
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